NetTargets has partnered with Cellkey, which provides a cutting-edge AI-based glycopeptide analysis platform, to discover biomarkers for early detection and treatment of cancer.
NetTargets Inc.
09 Jun 2021
NetTargets has partnered with Cellkey, which provides a cutting-edge AI-based glycopeptide analysis platform, to discover biomarkers for early detection and treatment of cancer.
NetTargets has been selected as one of the top 10 semifinalists among hundreds of drug discovery startups worldwide. The AI Discovery Award is an annual recognition by Nebius AI, a European AI-centric public cloud provider with global reach.
